Open Access Highly Accessed Open Badges Case report

Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report

Maximilian Gahr1*, Regina Gastl2, Markus A Kölle1, Carlos Schönfeldt-Lecuona1 and Roland W Freudenmann1

Author Affiliations

1 Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany

2 Department of Neurology, University of Ulm, Ulm, Germany

For all author emails, please log on.

Journal of Medical Case Reports 2012, 6:49  doi:10.1186/1752-1947-6-49

Published: 6 February 2012



There are limited treatment options for people with schizophrenia with cytochrome P450 2D6 ultrarapid metabolizer status who do not respond to amisulpride.

Furthermore, the literature does not provide evidence-based guidelines for this particular constellation.

Case presentation

We report the case of a 50-year-old Caucasian female patient with schizophrenia and cytochrome P450 2D6 ultrarapid metabolizer status who experienced an insufficient antipsychotic effect with amisulpride. She was successfully treated with melperone-augmented haloperidol.


This report yields melperone-augmented haloperidol as a possible pharmacological strategy in the described situation. In addition, our observations support the available evidence for the potential of melperone to act as an inhibitor of cytochrome P450 2D6.